Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data.

Robb AS, Carson WH, Nyilas M, Ali M, Forbes RA, Iwamoto T, Assunção-Talbott S, Whitehead R, Pikalov A.

J Child Adolesc Psychopharmacol. 2010 Feb;20(1):33-8. doi: 10.1089/cap.2008.0163.

PMID:
20166794
2.

[Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?].

Charpeaud T, Samalin L, Llorca PM.

Encephale. 2014 Feb;40(1):62-73. doi: 10.1016/j.encep.2013.12.002. Epub 2014 Jan 18. Review. French.

PMID:
24445245
3.

Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials.

Marder SR, West B, Lau GS, Pultz JA, Pikalov A, Marcus RN, Gutierrez-Esteinou R, Crandall DT.

J Clin Psychiatry. 2007 May;68(5):662-8.

PMID:
17503974
4.

Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia.

Citrome L, Du Y, Risinger R, Stankovic S, Claxton A, Zummo J, Bose A, Silverman BL, Ehrich EW.

Int Clin Psychopharmacol. 2016 Mar;31(2):69-75. doi: 10.1097/YIC.0000000000000106.

PMID:
26517202
5.

A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.

Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH.

Am J Psychiatry. 2008 Nov;165(11):1432-41. doi: 10.1176/appi.ajp.2008.07061035. Epub 2008 Sep 2.

PMID:
18765484
6.

The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.

Janicak PG, Glick ID, Marder SR, Crandall DT, McQuade RD, Marcus RN, Eudicone JM, Assunção-Talbott S.

J Clin Psychiatry. 2009 Jan;70(1):25-35. Epub 2008 Dec 2.

PMID:
19192472
7.

Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies.

Volavka J, Czobor P, Citrome L, McQuade RD, Carson WH, Kostic D, Hardy S, Marcus R.

J Clin Psychiatry. 2005 Nov;66(11):1362-6.

PMID:
16420071
8.

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW.

J Clin Psychiatry. 2002 Sep;63(9):763-71.

PMID:
12363115
9.

Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.

Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki J.

J Clin Psychopharmacol. 2008 Dec;28(6):601-7. doi: 10.1097/JCP.0b013e31818aaf6c.

PMID:
19011427
10.

Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia.

Docherty JP, Baker RA, Eudicone J, Mathew S, Marcus RN, McQuade RD, Mankoski R.

Schizophr Res. 2010 Jul;120(1-3):199-203. doi: 10.1016/j.schres.2010.03.040. Epub 2010 May 23.

PMID:
20547037
11.

Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes.

Correll CU, Zhao J, Carson W, Marcus R, McQuade R, Forbes RA, Mankoski R.

J Am Acad Child Adolesc Psychiatry. 2013 Jul;52(7):689-698.e3. doi: 10.1016/j.jaac.2013.04.018. Epub 2013 Jun 5.

PMID:
23800482
12.

Intramuscular aripiprazole in the control of agitation.

Currier GW, Citrome LL, Zimbroff DL, Oren D, Manos G, McQuade R, Pikalov AA 3rd, Crandall DT.

J Psychiatr Pract. 2007 May;13(3):159-69.

PMID:
17522559
13.

A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.

Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assunção-Talbott S.

J Clin Psychiatry. 2009 Oct;70(10):1348-57. doi: 10.4088/JCP.09m05154yel.

PMID:
19906340
14.

Intramuscular aripiprazole in the acute management of psychomotor agitation.

De Filippis S, Cuomo I, Lionetto L, Janiri D, Simmaco M, Caloro M, De Persis S, Piazzi G, Simonetti A, Telesforo CL, Sciarretta A, Caccia F, Gentile G, Kotzalidis GD, Girardi P.

Pharmacotherapy. 2013 Jun;33(6):603-14. doi: 10.1002/phar.1260. Epub 2013 Mar 15.

PMID:
23505124
15.
16.

Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.

Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG; Aripiprazole Study Group.

J Clin Psychiatry. 2003 Sep;64(9):1048-56.

PMID:
14628980
17.

Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial.

Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA.

J Clin Psychiatry. 2007 Jan;68(1):111-9.

PMID:
17284138
18.

Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.

Citrome L, Meng X, Hochfeld M, Stahl SM.

Hum Psychopharmacol. 2012 Jan;27(1):24-32. doi: 10.1002/hup.1254. Epub 2011 Dec 7.

PMID:
22161738
19.

A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia.

Chengappa KN, Goldstein JM, Greenwood M, John V, Levine J.

Clin Ther. 2003 Feb;25(2):530-41.

PMID:
12749512
20.

Aripiprazole: in adolescents with schizophrenia.

Sanford M, Keating GM.

Paediatr Drugs. 2007;9(6):419-23. Review.

PMID:
18052412

Supplemental Content

Support Center